慢衰灵口服液对充血性心力衰竭患者血浆可溶性细胞间粘附分子1水平的影响

探讨慢衰灵口服液对充血性心力衰竭患者血浆可溶性细胞间粘附分子 1水平的影响及其心脏保护机制。 1 2 0例充血性心力衰竭患者随机分为常规治疗组 (n =6 0 )和慢衰灵口服液组 (n =6 0 ) ,用酶联免疫吸附法检测两组充血性心力衰竭患者治疗前后及 4 0例正常对照者血浆可溶性细胞间粘附分子 1的水平。结果发现 ,常规治疗组和慢衰灵口服液组充血性心力衰竭患者血浆可溶性细胞间粘附分子 1水平较对照组显著增高 (P <0 .0 1 ) ,两组治疗后血浆可溶性细胞间粘附分子 1水平与治疗前相比显著降低 (P <0 .0 1 ) ,与对照组比较差异亦显著 (P <0 .0 1 ) ,治疗后慢衰灵口服液组血浆可溶性细胞间粘附分子 1水平与常规治疗组相比差异显著 (P <0 .0 1 )。结果提示 ,慢衰灵口服液具有降低充血性心力衰竭患者血浆可溶性细胞间粘附分子 1水平的作用 ,从而减缓充血性心力衰竭患者心室重塑的进程 ,进而改善心功能

The Effects of Manshuailing Oral Liquid on Soluble Intercellular Adhesion Molecular-1 Level in Patients with Congestive Heart Failure

Aim To investigate the effect and the heart protecting mechanism of manshuailing oral liquid on plasma soluble intercellular adhesion molecular 1 (sICAM 1) level in patients with congestive heart failure (CHF). Methods 120 patients of CHF were randomly divided into 2 groups. 60 cases in the routine treatment group received common therapy, and 60 cases in the manshunailing oral liquid treatment group were treated with additional manshuailing oral liquid except common therapy. 40 normal cases were taken as the control group. The plasma level of sICAM 1 was tested before and after 4 weeks management by enzyme linked immunosorbent assay (ELISA) method. Results The plasma concentration of sICAM 1 in both the treatment groups was higher than the control group even after treating (P<0.01). Compared with that of pretreating, the level of sICAM 1 decreased in both the treatment groups (P<0.01), but the magnitude of change was greater in the manshuailing oral liquid group than in the routine treatment group (P<0.01). Conclusion Manshuailing oral liquid may inhibit ventricular remodeling and improve heart function by decreasing the concentration of sICAM 1 in patients with CHF.